• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Utilization and cancer yield of BI-RADS 3 lesions detected on high risk screening breast MRI

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early stage breast cancer and avoid unnecessary biopsies, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

Utilization of MRI for breast cancer screening continues to increase, as it is the most sensitive modality to detect breast cancer. Yet, much more is known about short-term follow-up of probably benign findings (

Among the 6672 MRI screening exams performed in 3214 patients included in the study, 202 (3.0%) were assigned a BI-RADS 3. Among baseline exams, 8.3% (82/983) were assigned BI-RADS 3, compared to 2.1% (120/5689) of non-baseline exams (p

The results indicate BI-RADS 3 assessments are significantly more common in baseline versus non-baseline screening breast MRI exams, and BI-RADS 3 lesions on baseline exams have a lower cancer yield. Most cancers diagnosed on follow-up of BI-RADS 3 lesions are early stage and most are diagnosed at or before the 6-month follow-up. The results indicate that when employed sensibly, short-interval follow-up MRI is an appropriate technique to identify early stage breast cancer. “This study clarifies that probably benign assessments can be as useful for MRI as they are for mammography,” said co-author Leslie Lamb, MD, MSc, of Massachusetts General Hospital (MGH) and Harvard Medical School, both in Boston.

“Many patients and providers question the utility of BI-RADS 3 in MRI, particularly as some insurers do not cover the costs of the short interval follow-up MRIs. This study clarifies that short interval follow-up MRI is a valuable method of identifying early stage breast cancer while avoiding unnecessary biopsies.” noted co-author Christine Edmonds, MD, of the department of radiology at MGH.

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/bi-rads-breast-mri-utilization-and-cancer-yield.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Mass General Brigham Researchers Leverage Tumor Cells to Enhance Antitumor Immunity in Preclinical Cancer Models

November 3, 2025

Indoor Hydroponic Gardening Enhances Mental Well-Being and Quality of Life in Cancer Patients

November 3, 2025

New Alliance Launches Clinical Trial to Explore Exercise Benefits for Cancer Patients

November 3, 2025

Activating Immune Pathways in Tumors May Trigger Their Destruction

November 3, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1297 shares
    Share 518 Tweet 324
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    313 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    204 shares
    Share 82 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

EFT for Managing Kinesiophobia in Rheumatoid Arthritis Patients

Enhancing Safety of Implanted Orthopedic Devices with Biomaterial Vaccines

New Study Uncovers Variation in Viral Risk Among Bat Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.